Molecular therapy for Metabolic disorders: MiRNA-183 increases liver-X-receptor expression, protects aganist diet-induced weight-gain, and increases insulin-secreting cell mass and function via down regulation of its target genes, 20/November/2016, 10.30 am

Molecular therapy for Metabolic disorders: MiRNA-183 increases liver-X-receptor expression, protects aganist diet-induced weight-gain, and increases insulin-secreting cell mass and function via down regulation of its target genes, 20/November/2016, 10.30 am

Molecular therapy for Metabolic disorders: MiRNA-183 increases liver-X-receptor expression, protects aganist diet-induced weight-gain, and increases insulin-secreting cell mass and function via down regulation of its target genes, 20/November/2016, 10.30 am 150 150 Dr Boomi's Genom-2-Discovery Center

Significance of the study: 

Given that (1)  more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) the life-long painful injection/drug treatment required to treat DM; and (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult β-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free natural product-based drug.

From research findings to therapeutic opportunity:

This study suggests an MiRNA-based Regenerative therapy for DM.  MiRNA-183, by increasing the expression of its target gene,  it may: (1) increase the expression of modulator of lipid homeostasis liver X receptor (LXR)-α; (2) decrease plasma levels of triglyceride and cholesterol; (3) protect against diet-induced weight-gain; and (4) increase insulin-secreting cell mass and function. price-50

Thereby, it may increase insulin sensitivity  and leanness.  Thus, pharmacological formulations encompassing “MiRNA-183 or its activators or MiR-183 plus any of the known anti-metabolic compounds in use”  can be used to treat metabolic disorders, including Diabetes.

Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed information: How MiRNA-183 increases: (1) (LXR)-α expression; and (2) insulin-secreting cell mass and function. 

References:

Citation: Boominathan, L., Molecular therapy for Metabolic disorders: MiRNA-183  increases liver-X-receptor expression, protects aganist diet-induced weight-gain, and increases insulin-secreting cell mass and function via down regulation of its target genes, 20/November/2016, 10.29 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org

Share
Molecular therapy for tuberculosis: MiRNA-128-1 increases the expression of MKP-1, inhibits TLR2 signalling, secretion of Chemokine CXCL5, and recruitment of polymorphonuclear leukocytes (PMNs), decreases destructive pulmonary inflammation, promotes M. tuberculosis clearance and inhibits pulmonary tuberculosis via up-regulation of its target gene, 20/November/2016, 10.01 am
Anti-metastasis therapy: MiRNA-9600 increases the expression of tumor suppressor PTEN and inhibits proliferation, invasion and metastasis of cancer cells via down regulation of its target gene,21/November/2015, 10.38 am
Start Typing